Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Achieving patient engagement in pharmacovigilance: from high-income countries to lower and -middle-income countries with focus on Africa.

Autor: Sabblah GT; Food and Drugs Authority, Accra, Ghana.; PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands., Taxis K; PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands., Duwiejua M; School of Pharmacy, College of Health Sciences, University of Ghana, Legon, Ghana., Seaneke SK; Food and Drugs Authority, Accra, Ghana., van Puijenbroek E; PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.; Netherlands Pharmacovigilance Centre Lareb, 's-Herteogenbosch, The Netherlands., van Hunsel F; PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.; Netherlands Pharmacovigilance Centre Lareb, 's-Herteogenbosch, The Netherlands.

Publikováno v: Expert opinion on drug safety [Expert Opin Drug Saf] 2024 Dec; Vol. 23 (12), pp. 1493-1501. Date of Electronic Publication: 2024 Oct 19.

Sexual function and reproduction can be impaired in men with rheumatic diseases: A systematic review

Autor: Perez-Garcia, L.F., te Winkel, B., Carrizales, J.P., Bramer, W., Vorstenbosch, S., van Puijenbroek, E., Hazes, J.M.W., Dolhain, R.J.E.M.

Publikováno v: In Seminars in Arthritis and Rheumatism June 2020 50(3):557-573

The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration.

Autor: Fusaroli M; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy. michele.fusaroli2@unibo.it., Salvo F; Université de Bordeaux, INSERM, BPH, Team AHeaD, U1219, 33000, Bordeaux, France. francesco.salvo@u-bordeaux.fr.; Service de Pharmacologie Médicale, CHU de Bordeaux, INSERM, U1219, 33000, Bordeaux, France. francesco.salvo@u-bordeaux.fr., Begaud B; Université de Bordeaux, INSERM, BPH, Team AHeaD, U1219, 33000, Bordeaux, France., AlShammari TM; College of Pharmacy, Almaarefa University, Riyadh, Saudi Arabia., Bate A; Global Safety, GSK, Brentford, UK.; Department of Non-Communicable Epidemiology, London School of Hygiene and Tropical Medicine, London, UK., Battini V; Pharmacovigilance and Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Università degli Studi di Milano, Milan, Italy., Brueckner A; Novartis Pharma AG, Basel, Switzerland., Candore G; Medical Affairs and Pharmacovigilance, Bayer AG, Berlin, Germany., Carnovale C; Pharmacovigilance and Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Università degli Studi di Milano, Milan, Italy., Crisafulli S; Department of Medicine, University of Verona, Verona, Italy., Cutroneo PM; Unit of Clinical Pharmacology, Sicily Pharmacovigilance Regional Centre, University Hospital of Messina, Messina, Italy., Dolladille C; UNICAEN, EA4650 SEILIRM, CHU de Caen Normandie, Normandie University, Caen, France.; Department of Pharmacology, CHU de Caen Normandie, Caen, France., Drici MD; Department of Clinical Pharmacology, Université Côte d'Azur Medical Center, Nice, France., Faillie JL; Desbrest Institute of Epidemiology and Public Health, Department of Medical Pharmacology and Toxicology, INSERM, Univ Montpellier, Regional Pharmacovigilance Centre, CHU Montpellier, Montpellier, France., Goldman A; Department of Internal Medicine, Sheba Medical Center, Ramat-Gan, Israel.; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Hauben M; Pfizer Inc, New York, NY, USA.; Department of Family and Community Medicine, New York Medical College, Valhalla, New York, USA., Herdeiro MT; Department of Medical Sciences, IBIMED-Institute of Biomedicine, University of Aveiro, 3810-193, Aveiro, Portugal., Mahaux O; Global Safety, GSK, Brentford, UK., Manlik K; Medical Affairs and Pharmacovigilance, Bayer AG, Berlin, Germany., Montastruc F; Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Faculty of Medicine, Toulouse University Hospital (CHU), Toulouse, France.; CIC 1436, Team PEPSS (Pharmacologie En Population cohorteS et biobanqueS), Toulouse University Hospital, Toulouse, France., Noguchi Y; Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan., Norén GN; Uppsala Monitoring Centre, Uppsala, Sweden., Noseda R; Institute of Pharmacological Sciences of Southern Switzerland, Division of Clinical Pharmacology and Toxicology, Ente Ospedaliero Cantonale, Lugano, Switzerland., Onakpoya IJ; Department for Continuing Education, University of Oxford, Oxford, UK., Pariente A; Université de Bordeaux, INSERM, BPH, Team AHeaD, U1219, 33000, Bordeaux, France.; Service de Pharmacologie Médicale, CHU de Bordeaux, INSERM, U1219, 33000, Bordeaux, France., Poluzzi E; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy., Salem M; Health Canada, Ottawa, ON, Canada., Sartori D; Uppsala Monitoring Centre, Uppsala, Sweden.; Centre for Evidence-Based Medicine, Nuffield, Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Trinh NTH; PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Oslo, Norway., Tuccori M; Tuscany Regional Centre, Unit of Adverse Drug Reaction Monitoring, University Hospital of Pisa, Pisa, Italy., van Hunsel F; Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.; PharmacoTherapy, Epidemiology and Economics, University of Groningen, Groningen Research Institute of Pharmacy, Groningen, The Netherlands., van Puijenbroek E; Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.; PharmacoTherapy, Epidemiology and Economics, University of Groningen, Groningen Research Institute of Pharmacy, Groningen, The Netherlands., Raschi E; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy., Khouri C; Pharmacovigilance Department, Université Grenoble Alpes, Grenoble Alpes University Hospital, Grenoble, France.; UMR 1300-HP2 Laboratory, Université Grenoble Alpes, INSERM, Grenoble Alpes University, Grenoble, France.

Publikováno v: Drug safety [Drug Saf] 2024 Jun; Vol. 47 (6), pp. 585-599. Date of Electronic Publication: 2024 May 07.

Risks versus benefits of medication use during pregnancy: what do women perceive?

Autor: Mulder B, Bijlsma MJ, Schuiling-Veninga CCM, Morssink LP, van Puijenbroek E, Aarnoudse JG, Hak E, de Vries TW

Publikováno v: Patient Preference and Adherence, Vol Volume 12, Pp 1-8 (2017)

Bianca Mulder,1 Maarten J Bijlsma,1 Catharina CM Schuiling-Veninga,1 Leonard P Morssink,2 Eugene van Puijenbroek,3,4 Jan G Aarnoudse,5 Eelko Hak,1 Tjalling W de Vries6 1Groningen Research Institute of Pharmacy, Unit PharmacoTherapy, Epidemiology & Ec

Externí odkaz: https://doaj.org/article/c95cbddf3e6747bf90f86fc16c996d8b